Trading away our health: How trade and investment rules put corporate rights ahead of public health.
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
The National Farmers Union says the new deal’s extended patent protection for new pharmaceuticals must be reduced so that less expensive generic versions of new drugs can be available to consumers sooner.
The mutual recognition agreement for inspections of manufacturing sites for human medicines in their respective territories can make it faster and less costly for both sides to bring medicines to the market.
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement (FTA).
Three harmful provisions concerning pharmaceuticals and agriculture which were part of the RCEP have been withdrawn.
FTA Watch would like to urge the Thai negotiation team for the RCEP to have a
strong position to reject proposals on Intellectual Property Enforcement chapter.
US Democrats fear higher drug prices, trying to change text of trade deal
These practises open the door to Big Pharma companies and disastrous private health companies.
African governments must act immediately to address the AfCFTA’s potential negative implications for Africans’ health.
In its latest report on foreign trade barriers, the USTR, prompted by the pharmaceutical industry, takes aim at the pharmaceutical pricing and reimbursement policies in the European Union.
The Parliamentary Budget Officer (PBO) revealed that new intellectual property provisions in the Canada-United States-Mexico Agreement would cost Canadians as much as $169 million more per year for pharmaceutical drugs
The new version of NAFTA forbids the US Congress from curtailing Big Pharma’s patent monopolies on some of the world’s most expensive drugs.
Democrats in Congress contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump’s signature causes.
Some Democrats in the US, like Canada’s generic drug industry, warn that the new biologics rule would keep drug prices high by requiring citizens to wait longer before they can get their hands on lower-cost similar drugs known as biosimilars.
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts towards affordable health care and medicine.
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.